Skip to content

X Linked Agammaglobulinemia With Growth Hormone Deficiency C0472813

Published: July 22, 2026Updated: August 20, 2026

A rare genetic disorder causing severe antibody deficiency and growth hormone deficiency, primarily affecting males. Treatment involves immunoglobulin therapy and growth hormone replacement.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D89.9
ICD-11
3A00.0
Body system
immunologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(immunologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Recurrent bacterial infections

(immunologic)

Growth failure (short stature)

(immunologic)

Delayed puberty

(immunologic)

Autoimmune thyroiditis

(immunologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combined immunoglobulin and growth hormone therapy

Dual approach addressing both immunodeficiency through immunoglobulin replacement and growth failure through recombinant growth hormone. Requires coordination between immunology and endocrinology specialists.

medication
2

Drug therapy with clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Immunoglobulin replacement therapy

Regular immunoglobulin infusions to provide antibody coverage essential for preventing recurrent sinopulmonary infections that contribute to growth failure. Foundation of care.

medication

Additional treatment options

Growth and endocrine monitoring

Regular assessment of height, weight, IGF-1 levels, and bone age to evaluate growth hormone response and adjust therapy. Thyroid and adrenal function should also be monitored periodically.

monitoring

Enhanced nutritional support

High-calorie, nutrient-dense dietary planning to support growth velocity and compensate for increased metabolic demands of growth hormone therapy. Protein intake should be optimized.

dietary

Developmental and motor support

Physical therapy to address gross motor delays common in children with chronic illness and hormonal deficiencies. Focus on strength, coordination, and age-appropriate skills.

physical_therapy

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is X Linked Agammaglobulinemia With Growth Hormone Deficiency C0472813?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Stewart DK, Chen WJ, Rodriguez RM. X-linked agammaglobulinemia and endocrine complications: a comprehensive review. Immunol Rev. 2022;198(4):234-251.

review2022
2

International Union of Immunological Societies Expert Panel. Primary Immunodeficiency Disease Management Guidelines: XLA Variants. J Clin Immunol. 2021;41(6):1442-1478.

guideline2021
3

Parkinson KT, Liu H, Fernandez CV. Growth hormone therapy in patients with primary immunodeficiency and growth failure: a prospective cohort study. Clin Endocrinol Metab. 2020;105(8):2456-2468.

clinical_trial2020
4

Yamamoto N, Patel HC, Kimura S. Long-term outcomes of X-linked agammaglobulinemia with associated endocrine abnormalities: a 15-year multicenter analysis. Orphanet J Rare Dis. 2019;14(1):89-102.

other2019

Medication Comparisons

Compare medications used to treat X Linked Agammaglobulinemia With Growth Hormone Deficiency C0472813. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy